--- a
+++ b/clusters/3009knumclusters/clust_12.txt
@@ -0,0 +1,726 @@
+Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by PCR is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul
+HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant’s relevant medical history and/or current management of HIV infection
+HIV plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays (limit of detection: 75) within 4 weeks prior to registration
+Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
+Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
+HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;\r\n* HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
+Known history of HIV infection
+Human immunodeficiency virus (HIV) positive with CD4 count < (350) cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= (350) cells/microliter, and no known detectable viral load, at the time of study entry; note also that HIV testing is not required for eligibility for this protocol
+Positive test for HIV
+Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have an undetectable viral load\r\n* They must have a CD4 count of greater than 250 cells/mcL \r\n* They must not be receiving prophylactic therapy for an opportunistic infection
+Patients who are human immunodeficiency virus (HIV)-positive are eligible if: \r\n* CD4+ cell count greater or equal to 250 cells/mm^3\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts\r\n* Probable long-term survival with HIV if cancer were not present
+Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
+Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:\r\n1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3\r\n2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used\r\n3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
+STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
+Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to sub-study registration
+Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:\r\n* Cluster of differentiation (CD)4 cells >= 500/uL\r\n* Serum HIV viral load of < 25,000 IU/ml\r\n* No current antiretroviral therapy\r\n** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)
+Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3
+Individuals who are known to be human immunodeficiency virus (HIV) infected are eligible (note: HIV testing is not required for entry into the study)
+Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based tests
+Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:\r\n* Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3\r\n* History of acquired immune deficiency syndrome (AIDS) indicator conditions\r\n* Anti-retroviral therapy with any potent CYP3A4 inhibitor
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\r\n* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine\r\n* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine
+Patients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)\r\n* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed\r\n* Stavudine and zidovudine (AZT) are NOT allowed
+Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 1 registration; note also that HIV testing is not required for eligibility for this protocol
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART); and\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard PCR-based tests
+Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy\r\n* No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past 12 months other than historic CD4+ T-cell counts below 200 cells/mm^3\r\n* Expected long-term survival if lymphoma were not present
+Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to registration\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration\r\n* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4
+Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study
+Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:\r\n* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma\r\n* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma\r\n* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed\r\n* Zidovudine is not allowed\r\n* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed\r\n* Patients with multi-drug resistant HIV are not eligible
+Known human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
+Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy
+Patients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later date
+Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)
+Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
+HIV positive with CD4 count < 200 cells/microliter within 30 days prior to registration
+HIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count; (Note: HIV testing is not required for eligibility for this protocol as it is self-reported; this exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART)
+Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Severe, active co-morbidity defined as follows: \r\n* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
+The patient must NOT have a known positive test for human immunodeficiency virus (HIV); patients do not need to be screened for HIV; patients with HIV are excluded
+Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions\r\n* CD4 cells > 350 cells/mm^3\r\n* If on antiretroviral agents, must not include zidovudine or stavudine\r\n* Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART\r\n* Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactions
+No history of the following:\r\n* Autoimmunity requiring systemic immunosuppression within 2 years\r\n* Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following:\r\n** CD4 counts >= 350 mm^3\r\n** Serum HIV viral load of < 25,000 IU/ml
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
+HIV positive patients.
+HIV infection.
+Subject is known to be HIV positive.
+Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* CD4+ cells >= 350/mm^3 (nadir)\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this study
+HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL\r\n* NOTE: the term \licensed\ refers to a United States (U.S.) Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally\r\n* WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load
+Human immunodeficiency virus (HIV) test has been obtained within 42 days; participants who test positive for HIV cannot be enrolled on therapeutic part of study, but are still eligible for biology studies
+Participants known to be HIV positive (for therapeutic part of protocol, HIV participants are eligible for biology studies)
+ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient cannot have poorly controlled human immunodeficiency virus (HIV), or CD4 < 400; HIV positive patients are allowed on this study if they have a CD4 count >= 400, and are on a stable antiviral regimen
+ELIGIBILITY CRITERIA - PHASE II (ARM D): Patient cannot have poorly controlled HIV, or CD4 < 400; HIV positive patients are allowed on this study if they have a CD4 count >= 400, and are on a stable antiviral regimen
+Negative HIV test at screening
+Known history of HIV or AIDS
+Immunosuppressed status due to known human immunodeficiency virus (HIV) infection, severe uncontrolled diabetes, concurrent hematological malignancy, or other comorbidities
+Has a known history of HIV (HIV 1/2 antibodies), active / chronic Hepatitis B or C.
+HIV positive
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Positive serology for HIV.
+Patients who have previously tested positive for human immunodeficiency virus (HIV) are NOT excluded from this study (please note: testing of all patients wishing to enroll is NOT required), but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+COHORT 2: Has a known history of HIV (HIV 1/2 antibodies)
+HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection
+Seropositivity for HIV.
+Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy (testing is not part of the protocol)
+Known HIV positivity
+Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3; please note: HIV+ patients who enroll on this study may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4; adverse events in HIV+ patients will be reported separately
+Patients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the study
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Positive test for the human immunodeficiency virus (HIV) unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) and on highly active antiretroviral therapy (HAART) therapy
+Known seropositive for or positive viral load for human immunodeficiency virus (HIV) or positive viral loads for infectious hepatitis, type B (HBV) or C (HCV)
+HIV infection
+Any patient with a history of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV) is excluded; subjects on immune suppressive therapy for organ transplant are also excluded
+Patients known to be human immunodeficiency (HIV)-positive receiving anti-retroviral therapy are excluded from the study
+PROCUREMENT: Patients with active human immunodeficiency virus (HIV) positive at time of procurement (can be pending at the time of blood draw)
+A known history of HIV seropositivity or known immunodeficiency
+Known to be HIV-positive
+Known history of HIV.
+Known to be human immunodeficiency virus (HIV) positive or immunocompromised with posttransplant lymphoproliferative disorder (PTLD)
+Human immunodeficiency virus (HIV) positive at time of procurement cells for CTL generation
+Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration as long as:\r\n* CD4+ cell count >= 250 cells/mm^3\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the study drugs; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
+Participants with a known history of human immunodeficiency virus (HIV) are ineligible because of the potential for pharmacokinetic interactions with MCS110, dabrafenib, and trametinib with antiretroviral agents. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy
+Active infection or ongoing antiviral medication for viral infections including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for chronic conditions is not required; HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with selumetinib or osimertinib
+Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
+A known history of HIV
+Subjects with a known history of human immunodeficiency virus (HIV), including patients with controlled disease on antiretroviral therapy; HIV testing is not required as part of screening for this study
+Patients known to be HIV positive.
+Known active HCV, HBV, and/or HIV infection.
+Known HIV seropositivity
+Immunocompromised patients with increased risk of opportunistic infections, including known HIV-positive patients
+PROCUREMENT EXCLUSION CRITERIA: Patients with active human immunodeficiency virus (HIV) infection at time of procurement
+HIV positive
+EXCLUSION - TREATMENT: Active infection with HIV or HTLV
+Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibiotics
+Patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a cluster of differentiation (CD)4 count >= 200 cells/microliter within 180 days prior to registration as documented in the medical record; HIV testing is not required for eligibility for this protocol
+Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible
+Immunocompromised patients (other than that related to the primary oncologic diagnosis or to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive are not eligible
+HIV or hepatitis C - presence of viral load
+Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests
+Evidence of HIV infection or known HIV positive serology.
+Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:\r\n* CD4+ T-cells >= 250/mm^3\r\n* HIV sensitive to antiretroviral therapy\r\n* Zidovudine not allowed\r\n* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma\r\n* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma
+Individuals who are known to have acquired immunodeficiency syndrome (AIDS) (cluster of differentiation [CD] 4 < 200 or an AIDS-defining illness) or are known to be human immunodeficiency virus (HIV) positive and not on highly active antiretroviral therapy (HAART) are ineligible
+Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions
+Subject has active infection with HIV, HBV, HCV or HTLV
+Has known HIV
+HIV uninfected and infected women (without acquired immunodeficiency syndrome [AIDS] defining illness)
+On continuous antiretrovirals with cluster of differentiation 4 (CD4) count > 200 cells/ml with sustained undetectable viral load for at least 3 months; (HIV positive women)
+Not compliant with anti-retroviral therapy (HIV infected participants)
+CD4 count < 200 cells/ml and detectable viral load within the least 3 months (HIV infected participants
+Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
+Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in HIV-positive participants when indicated.
+Acquired immune deficiency syndrome (AIDS) due to the potential for increased complications from treatment; note, however, that HIV testing is not required
+Have a known history of HIV seropositivity
+Subjects with known HIV, active hepatitis B, or active hepatitis C (detectable RNA); HIV positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with durvalumab and/or tremelimumab; in addition, these subjects are at increased risk of lethal infections when treated with immunosuppressive therapy
+Have known immune system disorders (including acquired immunodeficiency syndrome [AIDS], HIV infection or hepatitis B or C); eligible patients must have a negative HIV test result within 4 weeks prior to study initiation
+Immune deficiency disease or known history of HIV, HBV, HCV
+The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
+Severe, active comorbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\r\n* Uncontrolled, clinically significant cardiac arrhythmias\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter\r\n** Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to Step 1 registration\r\n** Note: HIV testing is not required for eligibility for this protocol
+Human immunodeficiency virus (HIV) positive or other acquired immunodeficiency that, as determined by the PI, interferes with the assessment of PID severity and/or the attribution of clinical manifestations of immunodeficiency to a PID
+Know HIV virus infection
+Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration;\r\n* Transmural myocardial infarction within the last 6 months prior to registration;\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
+Known positiv test for HIV
+Positive HIV serology or viral RNA
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immune-compromised patients
+Known HIV infection.
+Known to have lymphoma related to HIV or acquired immune deficiency syndrome (AIDS)
+PROCUREMENT EXCLUSION CRITERIA: Patients with active human immunodeficiency virus (HIV) infection at time of procurement (can be pending at the time of blood draw)
+HIV positive
+If patient is known to be human immunodeficiency virus (HIV) positive, they will not be eligible for the protocol; HIV testing is not mandatory prior to protocol enrollment
+Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated; note: HIV testing is not required for entry into this protocol
+EXCLUSION - TREATMENT: Known primary immune deficiency or HIV positivity
+Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C; HIV patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
+Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and those severely immunocompromised will be excluded; however, no patients will be tested for HIV
+Known HIV infection.
+PART II: Negative serology for anti-HIV-1/2 and anti-HTLV 1/2
+Positive serology for HIV or hepatitis C
+Patients with documented immunodeficiency such as HIV infection.
+Positive HIV serology (previous records acceptable)
+Multidrug resistant HIV not amenable to long-term suppression based on either or both:\r\n* Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient to render effective HIV control unattainable\r\n* HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level resistance such that a combination regimen comprised of agents from at least two drug classes cannot be devised to suppress HIV long-term\r\n* Refusal to adhere to HAART
+Patients with human immunodeficiency virus (HIV)-1 may be eligible if they meet the following conditions:\r\n* CD4 cell count > 350 cells/mm3 obtained within 90 days prior to study start.\r\n* Plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays for > 2 years on combination anti-retroviral therapy (cART). \r\n* Plasma HIV-1 RNA level of less than 40 copies/mL obtained by the Abbott m2000 assay or less than 20 copies/mL by Roche Taqman version (v)2.0 assay within 90 days prior to study start.\r\n* Plasma HIV-1 RNA greater than or equal to 0.4 copies/mL by single copy assay within 120 days prior to entry.\r\n* Receiving a stable cART regimen containing at least 3 agents (not including ritonavir if less than a 200 mg total daily dose) with no change in the components of antiretroviral therapy for at least 90 days prior to study entry.
+TREATMENT WITH SJCAR19: History of HIV infection
+Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)
+Patients who are known to be serologically positive for human immunodeficiency virus (HIV). This includes HIV patients on antiretroviral therapy due to the potential for pharmacokinetic interactions with olaparib
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs
+Patients known to be human immunodeficiency (HIV)-positive must not have multi-drug resistant HIV infection, CD4 counts < 150/ul or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions; serologic screening for HIV is required within the 6 months prior to study enrollment
+Patients serologically positive for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR); HIV positive patients must have CD4 count >= 300 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy and have no reported opportunistic infections within 12 months prior to enrollment
+Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated; Note: HIV testing is not required for entry into this protocol
+Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)
+Severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)
+Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
+Known history of HIV
+Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). No HIV testing is required unless mandated by local health authority.
+Human Immunodeficiency virus (HIV) positive patients are included if CD4+ T-cell count > 200 cells/uL; on stable antiretroviral therapy for > 1 year with HIV viral load < 200 copies/mL, and no history of opportunistic infections in > 1 year
+Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.
+HIV infection
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following: \r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)\r\n* After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible\r\n* At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3\r\n* At the time of study entry the HIV viral load must be undetectable by standard laboratory assay \r\n* During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status\r\n* No history of non-adherence to cART and willing to adhere to cART while on study\r\n* Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:\r\n** Efavirenz not allowed\r\n** Stavudine not allowed\r\n** Zidovudine not allowed\r\n* Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management
+Known HIV or AIDS-related illness
+Participant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.
+Human immunodeficiency virus (HIV) infected patients (if HIV positive)\r\n* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:\r\n** No history of acquired immune deficiency syndrome (AIDS) defining illness other than a historic CD4+ T-cell nadir < 200/mm^3\r\n** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:\r\n*** The CD4+ T-cell counts were generally in excess of 300/mm^3\r\n*** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy\r\n*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms\r\n*** Zidovudine is not allowed as part of the anti-HIV therapy
+HIV-positive; documentation of HIV-1 infection by means of any one of the following: \r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider\r\n* Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name)\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay\r\nNOTE: A “licensed” assay refers to a United States (U.S.) Federal Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
+Has active human immunodeficiency virus (HIV) infection (as manifested by presence of HIV 1/2 antibodies and/or positive HIV enzyme-linked immunosorbent assay [ELISA]/western blot assays)
+Human immunodeficiency virus (HIV) infection as detected through any laboratory method (e.g., enzyme-linked immunosorbent assay, Western Blot, RNA PCR). [Note: Testing to confirm the absence of HIV infection is required at screening unless testing was performed by the local laboratory within 6 months prior to screening.]
+Patients who are HIV positive (by self-report) or have clinical or laboratory features indicative of AIDS.
+Known uncontrolled human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); patients with documented controlled HIV infection (CD4 > 200 and undetectable viral load) will be included
+Human immunodeficiency virus (HIV) positive with detectable viral load, or anyone not on stable anti?viral (highly active antiretroviral therapy [HAART]) regimen
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary
+Patients with positive human immunodeficiency virus (HIV) status and currently requiring treatment with agents known to sensitize to irradiation, such as protease inhibitors, will be excluded
+In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)
+Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV infected patients.
+HEALTHY SUBJECT: Be free of chronic illness, without known heart, lung, kidney, bleeding disorders, infectious disease (HIV, HBV or HCV infection)
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.
+Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
+Known human immunodeficiency virus (HIV) or a history of active hepatitis B or C as evidenced by laboratory abnormalities in addition to positive serology; testing is not required for patients not suspected of having these conditions
+Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
+Human immunodeficiency virus (HIV)-positive patients are excluded because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
+Immunocompromised patients, e.g. patients known to be serologically positive for HIV. Patients do NOT need to be tested for HIV in order to enroll on study
+History of positive human immunodeficiency virus (HIV)?1 or HIV?2 serologies or nucleic acid test
+Subject has active infection with HIV, HBV, HCV or HTLV
+Human immunodeficiency virus (HIV)-positive patients are eligible provided they meet all the other protocol eligibility criteria including the following:\r\n* Undetectable HIV viral load by standard clinical assay\r\n* Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy\r\n* CD4+ T cell counts of 200/mm^3 or greater\r\n* No acquired immunodeficiency syndrome (AIDS)-defining events other within the past 12 months\r\n* Near normal life expectancy if not for the presence of the cancer\r\nAlso, HIV-positive patients must not be on HIV medications considered to be inhibitors or inducers of CYP3A4
+Human immunodeficiency virus (HIV) positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:\r\n* Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n** Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* CD4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within 30 days of enrollment
+Known HIV, HBV, or HCV infection;
+Known human immunodeficiency virus (HIV)-positive unless on highly active antiretroviral therapy (HAART), and/or known Hepatitis B or C on treatment. Drug interactions between those agents and these experimental agents are wholly unknown (screening not required).
+Known HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
+Human immunodeficiency virus (HIV)-positive patients may be considered for this study only after consultation with a National Institute of Allergy and Infectious Diseases (NIAID) physician
+Known history of HIV infection (testing not mandatory).
+HIV-positive tetralogy of fallot (TET) patients are ineligible
+Participant has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.
+History of immunosuppression or autoimmunity, including human immunodeficiency virus (HIV), and organ or stem cell transplant, or an autoimmune condition previously treated with immunosuppressive therapy
+Patients who are HIV positive (by self-report) or have clinical or laboratory features indicative of AIDS.
+If HIV positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment
+Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)
+Patients with human immunodeficiency virus (HIV) are eligible for the study provided they meet the other protocol criteria in addition to the following: \r\n* Undetectable HIV load by standard polymerase chain reaction (PCR) clinical assay\r\n* Absolute CD4 count of >= 200 mm^3\r\n* Willing to maintain adherence to combination antiretroviral therapy\r\n* No history of acquired immunodeficiency syndrome (AIDS) defining condition (other than lymphoma or CD4 cell count < 200 mm^3)\r\n* Likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma\r\n**Patients with evidence of hepatitis B virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy\r\n** Patients with previously treated and eradicated hepatitis C virus (HCV) who have minimal hepatic injury are eligible
+Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on antiretroviral therapy (ART)—due to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
+Known to be positive for the human immunodeficiency virus (HIV); note: HIV-testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible
+HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of ART (at least three different medications) by a licensed health care provider (documentation may be a record of an antiretroviral therapy (ART) prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: a “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studies
+Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic hepatitis B or C.
+Known human immunodeficiency virus (HIV) positive (+) patients; EXCEPTION: if they meet the following additional criteria =< 28 days prior to registration:\r\n* CD4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger (m) ribonucleic acid (RNA)/mm^3 if on combination antiretroviral therapy (cART) or < 10,000 copies HIV mRNA if not on cART\r\n• No zidovudine or stavudine as part of cART
+Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by PCR is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul
+Known carriers of HIV antibodies
+Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
+Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS] or other immune depressing disease); testing is not mandatory
+Patients should have no evidence, as listed below, of being immunocompromised:\r\n• Human immunodeficiency virus (HIV) positivity due to the potential for decreased tolerance and risk for severe side effects\r\n• Hepatitis B or C positivity
+Any HIV status
+Known history of HIV, HBV or HCV infection.
+Known HIV-infected patients
+Known human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active antiretroviral therapy (HAART)
+Has a known history of human immunodeficiency virus (HIV); HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
+Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy may be eligible if there are no pharmacokinetic interactions with the agents used on the study, stable on chimeric antigen receptor T cell (CART) therapy and cluster of differentiation (CD)4 is > 200 and viral load is undetectable
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+Human immunodeficiency virus (HIV) virus infection irrespective of viral load, treatment status, or cluster of differentiation 4 (CD4) count, or acquired immunodeficiency syndrome (AIDS)-related illness; HIV testing is not required by this protocol
+Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs
+HIV positive
+Active autoimmune disorders, including patients known to be human immunodeficiency virus (HIV) positive, or those requiring chronic steroid administration (excluding inhaled steroids)
+Human immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing
+nEGFR positive
+Active infection (requiring oral or IV antibiotics or antiviral therapy) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated; known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
+PRIOR TO CELL PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis C virus (HCV) (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
+PRIOR TO LYMPHODEPLETION: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
+PRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral load
+Known HIV-positive or Hepatitis C
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Willing to have documentation of HIV status
+A recognized immunodeficiency disease including human immunodeficiency virus (HIV) infection (and other cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary, congenital or acquired immunodeficiencies).
+Patients with other diseases that in the opinion of the treating physician pose a higher risk for treatment with ibrutinib therapy including active human immunodeficiency virus (HIV) infection and bleeding disorders
+Known history of HIV, HBV or HCV infection.
+Known positive for HIV
+Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immunodeficiency syndrome (AIDS) indicator conditions
+Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past 6 months. If HIV+ positive, patient will be eligible if: his/ her CD4+ count ? 300/?L; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART).
+Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
+Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
+Known to be HIV-positive
+Patients who are known to have HIV infection/seropositivity.
+Patients with well controlled human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and viral load is < 50 copies/ml
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial; patients with HIV on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior acquired immunodeficiency syndrome (AIDS) defining conditions and adequate CD4 count (> 400) are eligible
+Immune deficiency disease or known history of HIV, HBV, HCV
+For dose-escalation cohort only, known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required; HIV positive patients will be eligible for the dose-expansion cohort
+Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHuman immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
+PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
+PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on combination antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
+PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/?L) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
+Human Immunodeficiency Virus (HIV)-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
+AT THE TIME OF INFUSION: HIV positivity
+HIV-positive
+Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
+Patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine, and must have a cluster of differentiation (CD)4 count > 100/mm^3 and virus load < 5000 copies/ml, and are placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
+Not be in an immunosuppressed state (e.g. human immunodeficiency virus positive [HIV +], use of chronic steroids [> 1 month])
+Because patients with immune deficiency are not expected to respond to this therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the study
+Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last six months\r\n* Transmural myocardial infarction within the last six months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other chronic respiratory illness requiring hospitalization within the last six months\r\n* Human immunodeficiency virus (HIV)-positivity with cluster of differentiation (CD)4 count < 200 cells/microliter; Note that HIV-positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter no more than 30 days prior to registration; Note also that HIV testing is not required for eligibility on this protocol\r\n* End-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)
+Known human immunodeficiency virus (HIV)-positive individuals; high-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs; a clinical trial designed to address these interaction issues is more appropriate than this phase 2 study
+HIV-1 seropositive
+Known HIV, or active hep B or hep C infection (detected positive by PCR).
+Patients with a detectable human immunodeficiency virus (HIV) viral load or who are HIV-positive AND have a resistant genotype
+Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: \r\n* Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition\r\n* Cluster of differentiation (CD)4 cell count >= 250\r\n* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone\r\n* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449
+PROCUREMENT: Patients with active human immunodeficiency virus (HIV) infection at time of procurement (can be pending at the time of blood draw)
+PART 2: History of HIV infection
+Subjects who are known to be HIV positive
+Immunosuppression (human immunodeficiency virus [HIV] positive, heme/oxygenase [h/o] transplantation, lupus on immunosuppressive medication, etc.)
+Patients with known HIV disease
+Known history of HIV infection.
+Known history of HIV, HBV or HCV infection.
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
+Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of screening; research participants with any signs of symptoms of active infection, positive blood cultures or radiological evidence of infections
+Comorbid conditions that, in the opinion of the investigator, would complicate safety or compliance such as known human immunodeficiency virus (HIV) or current substance abuse
+Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections
+HIV positive.
+Patients currently known to be positive for, HIV, hepatitis B or C.
+The patient has a history of human immunodeficiency virus (HIV) or other known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions
+Known human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination anti-retroviral therapy; screening for HIV status will not be performed
+Known to be seropositive for human immunodeficiency virus (HIV); an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
+Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded
+RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:\r\n* Long term survival expected were it not for the cHL\r\n* HIV viral loads undetectable by standard clinical HIV testing\r\n* Willing to adhere to effective combination antiretroviral therapy
+Must not be HIV, HBV or HCV positive
+Known immunosuppressed conditions or active immunosuppressive therapy such as organ transplantation (including bone marrow transplant), high dose steroids, or human immunodeficiency virus (HIV); although a documented negative HIV test is not mandatory for enrollment, patients felt to have a high clinical suspicion for HIV will need to test negative prior to enrollment; use of topicals or eye drops containing steroids is acceptable; inhaled steroids are excluded
+Patients who are known to be HIV or hepatitis C positive.
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+Known HIV-positive serology.
+Any HIV status
+For patients with HIV-associated KS:\r\n* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines\r\n* Must have been receiving HAART for at least one month\r\n* Must have achieved an HIV viral load (VL) < 10,000 copies/mL
+Serology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
+Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the study
+Patients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible
+Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including high-dose corticosteroids
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+If there is clinical suspicion of acquired immune deficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test must be done within 42 days prior to registration; Note: HIV positive patients with a cluster of differentiation (CD)4+ T cell count > 200 per uL of blood and > 14% of all lymphocytes are eligible for this trial
+Severe, active co-morbidity, including but not limited to:\r\n* Unstable angina within the last 6 months without subsequent corrective cardiovascular procedure\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Hepatic insufficiency with AST, ALT, or bilirubin > 2 x upper limit of normal, clinical jaundice, and/or coagulation defects\r\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; patients who are HIV seropositive but do not meet criteria for diagnosis of AIDS are eligible for study participation
+Known history of human immunodeficiency virus (HIV) seropositivity as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agent
+No uncontrolled bacterial, viral, or fungal infection (infection is permitted if there is evidence of response to medication)\r\n* Note: human immunodeficiency virus (HIV)-infected patients are potentially eligible; eligibility of HIV-infected patients will be determined on a case-by-case basis
+HIV infection
+Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
+Known HIV positivity
+Those who are HIV-positive will be excluded from the study
+Patients known to be human immunodeficiency virus (HIV)-positive (the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population)
+Patients with a known history of HIV.
+Known HIV positive patients
+Known to be HIV-positive
+Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV-infected participants
+Diagnosis of HIV or evidence of active HBV or HCV
+Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies); patients with treated HIV, as evidenced by stable CD4 > 200 for at least 6 months, are eligible
+HIV infection or a known HIV-related malignancy.
+Known HIV, HBV, or HCV infection.
+Human immunodeficiency virus (HIV)-positive patients are ineligible due to the risks associated with immune checkpoint blockade
+Known seropositive for HIV
+Patients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the study
+Known HIV-positive
+Patients who are HIV positive
+Patients who are known to be HIV-positive.
+Subject has known HIV infection
+Known to be HIV+
+Positive results from HIV serology testing, if any available.
+History of HIV infection.
+Patients known to be HIV positive are ineligible.
+HIV positive
+Known HIV positive or on active anti-retroviral therapy
+History of HIV positive
+Known history of HIV or AIDS.
+Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active antiretroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR) -based tests
+Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 4 weeks prior to randomization:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) and;\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Human immunodeficiency virus (HIV) infected patients (defined as HIV-1/HIV-2 antibody positive).
+Known HIV infection.
+Known history of HIV (HIV 1/2 antibodies).
+Evidence of active HepB, HepC, or HIV infection
+Participants must have a negative human immunodeficiency virus (HIV) antibody/antigen test and negative Chlamydia (C.) trachomatis/Neisseria (N.) gonorrhea nucleic acid amplification test (NAAT)
+REGISTRATION TO TREATMENT (STEP 1): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3
+REGISTRATION TO TREATMENT (STEP 2): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3
+Known infection with HIV (testing of patients not known to be infected with HIV is not required prior to study entry)
+Evidence of immune suppression due to: a) known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); b) known leukemia or lymphoma; c) those who require high dose steroids (> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment) or other immunosuppressive therapies (> 2 weeks); d) active hepatitis B or C; e) congenital or acquired cellular and/or humoral immune deficiency; f) other signs or symptoms of immune system suppression or concurrent opportunistic infection
+Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Patient with human immunodeficiency virus (HIV) who require anti-viral or supportive care that interacts with the study drugs are not eligible
+Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Anti-retroviral agents are known to have potential adverse pharmacokinetic interactions with nivolumab and/or BMS-813160. IN addition, patients not on anti-retroviral agents, regardless of HIV viral load, are at increased risk of lethal infections with marrow-suppressive therapy including chemotherapy. Testing for HIV must be performed at sites mandated by local requirements.
+Positive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C, active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active HIV, Hep B, or Hep C. (Note: If positive results are not indicative of true active or chronic infection, the patient can be treated.)
+Positive screening tests for HIV, Hep B, and Hep C. If positive results are not indicative of true active or chronic infection, the patient can be treated.
+For human immunodeficiency virus (HIV)+ patients: documented HIV-1 infection with CD4 count > 200 cells/mm^3 and viral load < 75 copies/mL, within 28 days of day 0.
+Other untreated coexisting HIV related malignancies.
+Positive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, and Hep C; if positive results are not indicative of true active or chronic infection, the patient can be treated
+HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol
+Known human immunodeficiency virus (HIV)-1 infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site; United States (U.S.) participants only: alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either:\r\n* Approved diagnostic tests, or\r\n* The referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n** Participants enrolled outside the U.S. must have a confirmatory diagnostic test sequence as appropriate per national standards, detailed as above, performed regardless of prior documented HIV status; for HIV-negative participants, testing must be performed no more than 1 month prior to study enrollment; NOTE: the term “licensed” refers to a U.S. Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme/chemiluminescence immunoassay (E/CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA) viral load
+No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies
+Human immunodeficiency virus (HIV)-positive subjects positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive subjects must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test
+Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:\r\n* Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy\r\n* Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and\r\n* Have no evidence of opportunistic infections
+History of active primary immunodeficiency including, but not limited to acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be immunosuppressive; patients with known HIV, CD4 counts >= 200/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Patients with known human immunodeficiency virus (HIV), hepatitis B or C infections; testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patient
+ARM B: Known HIV infection
+Immunocompromised patients, including patients known to be HIV positive
+Patients positive for human immunodeficiency virus (HIV) are not excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
+Patients with known human immunodeficiency virus (HIV) infection are eligible if being treated with non-interacting antiretroviral (ARV) agents or be willing to stop ARV for the protocol
+Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:\r\n* No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3\r\n* No antiretroviral therapy with overlapping toxicity such as myelosuppression\r\n* HIV viral loads below the limit of detection\r\n* No history of highly active antiretroviral therapy (HAART)-resistant HIV
+Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following (HIV testing is not required for study enrollment):\r\n* CD4+ cell count >= 250/mm^3\r\n* HIV viral loads undetectable by standard clinical tests
+HIV-1 seropositive
+HIV plasma viral load < 50 copies/ml
+Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
+Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active anti-retroviral therapy (HAART) is allowed
+The first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD)4 counts >= 350/mm^3 are allowed to participate if the following criteria are met:\r\n* Maintained on stable antiretroviral therapy with no significant drug interactions, and \r\n* No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (> 2 years from enrolling in trial), and \r\n* Physician providing patient’s care for HIV must also approve of patient entering the study
+Known history of immunodeficiency disorder other than HIV-positive status
+Seronegative for human immunodeficiency virus (HIV) antibody; Note: the experimental treatment being evaluated in this protocol depends on an intact immune system
+Patients with a known history of human immunodeficiency virus (HIV) seropositivity: must have undetectable viral load using standard HIV assays in clinical practice; must have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12 months prior to re-registration
+Patients with a known history of human immunodeficiency virus (HIV) seropositivity: 1. Must have undetectable viral load using standard HIV assays in clinical practice; 2. Must have cluster of differentiation (CD)4 count >= 400/mcL; 3. Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); 4. Must not be newly diagnosed within 12 months prior to re-registration
+Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to re-registration
+Patients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with 3 or more drug anti-retroviral regimen and virus load less than 50 copies/ml and CD4 count greater than 250 cells/ml, and no concurrent opportunistic infection or other malignancy
+HIV seropositive at or before the time of lymphoma diagnosis; all HIV positive patients are eligible regardless of HIV viral load or antiviral therapy (ART) status; all patients on study will receive ART as per standard guidelines
+Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
+Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of differentiation (CD)4 count is =< 200 cell/mm^3 or if receiving antiretroviral therapy
+Severe, active co-morbidity, defined as follows:\r\n* Diagnosis of type I or type II diabetes mellitus\r\n* Uncontrolled neuropathy >= grade 2 regardless of cause\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
+Patients with known human immunodeficiency virus (HIV) who have cluster of differentiation (CD)4+ T cell counts >= 500 cells/mm^3 and who do not require antiretroviral therapy are eligible
+Patients with absolute lymphocyte count of < 500, who are known to be human immunodeficiency virus (HIV) positive, who have clinically significant active autoimmune disease, or are receiving immunosuppression following solid organ or stem cell transplant
+Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking anti-retroviral therapy that may have a potential overlapping toxicity with the study therapy are not eligible
+Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible
+Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
+Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
+Patients with evidence of human immunodeficiency virus (HIV) seropositivity and/or positive polymerase chain reaction (PCR) assay, human T-cell leukemia virus type (HTLV)1/HTLV2 seropositivity
+Human immunodeficiency virus (HIV)-positive patients will be excluded unless antiretroviral therapy can be safely withheld during chemotherapy administration, based on clinical determination of infectious disease team evaluation
+No human immunodeficiency virus (HIV) disease; patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies
+Patients with known human immunodeficiency virus (HIV) infection are ineligible due to risk of pharmacokinetic interactions between anti-retroviral therapy and the study drugs, as well as potential for significant immunosuppression and serious infections with mTOR inhibition
+HIV-positive subjects with a CD4 count < 200 cells/?L are excluded due to the increased risk of lethal infections when treated with marrow-suppressive chemotherapy(87)\r\n* NOTE: subjects with HIV infection and a CD4 count >= 200 cells/?L are eligible but combination antiretroviral therapy should be held during administration of chemotherapy due to the potential for pharmacokinetic interactions with decita-bine, cytarabine or daunorubicin. Antiretroviral therapy may be resumed 24 hours after completion of the last dose of induction chemotherapy
+Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 counts < 200
+Human immunodeficiency virus (HIV) seropositive, with positive confirmatory nucleic acid test
+Patients with human immunodeficiency virus (HIV) infection (antibody positive with positive confirmatory molecular test)
+Patient must have documentation of negative human immunodeficiency virus (HIV)-1 testing within 6 weeks prior to study registration (separate counseling and consent as per institutional guidelines)
+Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; CD4+ count > 400/ul; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV RNA/mL; no history of acquired immunodeficiency syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapy
+Severe, active comorbidity, defined as follows:\r\n* Unstable angina in the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immunocompromised patients
+Documentation of HIV infection at any time prior to study entry; documentation may be molecular (detectable viral ribonucleic acid [RNA] by polymerase chain reaction [PCR]), serologic (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot), or other federally approved licensed HIV test; prior documentation of HIV seropositivity is acceptable
+Patients with known human immunodeficiency virus (HIV) are excluded; appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future
+Known HIV positivity
+Donors: HIV positive
+Patients with HIV disease are eligible for this study provided that:\r\n* Patients will be seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n* Must be on a maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* Cluster of differentiation (CD)4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within one month of enrollment
+HIV infection
+Patients known to be human immunodeficiency virus (HIV) positive and receiving highly active anti-retroviral therapy (HAART)
+Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on ART—due to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
+Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
+Known HIV or AIDS-related illness
+Current clinically active infectious disease (including positive HIV serology or viral RNA)
+Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate cluster of differentiation 4 (CD4) counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria
+HIV positive test within 8 weeks of screening
+Known history of infection with HIV.
+Known history of infection with HIV.
+HIV positive patients
+Known HIV (HIV testing will be performed at screening if required by local regulations) in participants to be pretreated with obinutuzumab
+Positive human immunodeficiency (HIV) test at screening or at any time prior to screening
+Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study
+Known infectious disease including HIV positivity or AIDS-related illness, HBV and HCV
+Known HIV or AIDS
+Relevant diseases or clinical situations which may increase patient's risk: History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV). Known muscular disease or functional alteration
+Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
+Immunocompromised patients, including patients with known HIV infection;
+Known history of testing positive for HIV or AIDS
+Patients with HBV, HCV or HIV infection
+Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions (other than the presenting DLBCL) or post-transplant lymphoproliferative disorder (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV) on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior AIDS defining conditions and adequate CD4 count (> 400) are eligible
+HIV negative
+HIV positive patients with advanced immune suppression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non-lymphoma related death within 12-months due to other acquired immune deficiency syndrome (AIDS) complications should not be enrolled on the study
+Patients who are known to be human immunodeficiency virus positive (HIV+) may be eligible providing they meet all of the following additional criteria:\r\n* Patients must have no history of acquired immunodeficiency syndrome (AIDS) defining events\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART
+Has a congenital or acquired immunodeficiency, including subjects with known history of infection with human immunodeficiency virus (HIV) NOTE: HIV-positive subjects who are taking antiretroviral therapy are ineligible due to potential PK interactions with tazemetostat.
+Has a known history of HIV (HIV 1/2 antibodies).
+Known history of HIV positive status
+Active infection with HIV, HBV, HCV or HTLV as minimally defined below:
+Positive serology for HIV.
+No known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 (cluster of differentiation 4) counts >350, with no detectable viral load on quantitative polymerase chain reaction test
+Patients testing positive to one of the following viruses: HIV, HBV and HCV within the last 6 months;
+Subjects with known HIV infection
+Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No evidence of co-infection with hepatitis B or C\r\n* CD4+ cell count >= 400/mm^3\r\n* No evidence of resistant strains of HIV
+If there is clinical suspicion of acquired immunodeficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test is recommended within 42 days prior to registration; Note: HIV positive patients without AIDS are eligible for enrollment on this study
+Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
+Disease or condition that would preclude safe use of TheraSphere, including concurrent dialysis treatment, or unresolved serious infections including patients who are known HIV positive
+Patients with active infections including known human immunodeficiency virus (HIV) are not eligible; HIV positive patients on highly active anti-retroviral therapy (HAART) with undetectable blood HIV levels are eligible; patients with a history or serological evidence of exposure to hepatitis B without active infection are eligible for this study
+Patients who are human immunodeficiency virus (HIV)+ (HIV+ patients registered at Fred Hutchinson Cancer Research Center [FHCRC] should be offered treatment on Protocol 1410)
+Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 1 registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
+Positive HIV test at screening (except in cohort 3, HPV-associated cancers)
+Patients who are known to be human immunodeficiency virus (HIV) positive (+) may be eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n• CD4 cells >= 500/mm^3\r\n• Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n• No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this study
+HIV infection
+Evidence of immune suppression due to: \r\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\r\n* Known leukemia or lymphoma\r\n* Those who require high dose steroids or other immunosuppressive agents\r\n* Known hepatitis B or C infection \r\n* Congenital or acquired cellular and/or humoral immune deficiency\r\n* Other signs or symptoms of immune system suppression
+Human immunodeficiency virus positive (HIV+) patients will be considered eligible if they are on highly active anti-retroviral therapy (HAART) and have a cluster of differentiation (CD)4 count of >= 200/ul (HIV+ patients who are on HAART and have a CD4 count < 200/ul are eligible if the plasma viral load is below the level of detection according to the local assay)
+HIV+ patients who are not on HAART or have a CD4 count of < 200/ul in the presence of detectable plasma viral load according to the local assay
+In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)
+Known infection with HIV, HBV or HCV.
+Human immunodeficiency virus (HIV) infection without acquired immune deficiency syndrome (AIDS)-defining criteria are eligible
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
+Patients who are HIV positive with a detectable viral load > 750 copies/ml on adequate retroviral therapy must be evaluated for HIV drug resistance test (HIV-1 genotype); these patients may be enrolled only after discussion with the principal investigator (PI) and the infectious disease team
+HIV related disease or known or suspected HIV+
+Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration\r\n* Transmural myocardial infarction within the last 6 months prior to registration\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) 4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
+Patients who are known to be human immunodeficiency virus (HIV) positive must have a normal cluster of differentiation (CD)4 count and undetectable viral load
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+Patients with human immunodeficiency virus (HIV) are eligible if their CD4 count is >= 350 cells/mm^3 and if they are not taking prohibited cytochrome (CYP)-interacting medications
+Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to be HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis B or C are not eligible for this study; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
+Clinically significant autoimmune disorders or conditions of immunosuppression; patients with AIDS or HIV-1 associated complex or known to HIV antibody seropositive or known to be recently PCR+ for hepatitis B or C virus are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
+Known to be positive for human immunodeficiency virus (HIV) antibody; NOTE: Does NOT need to be repeated if pre-transplant screening test was negative
+Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
+Subjects with HIV infection.
+HIV seropositivity
+Human immunodeficiency virus (HIV)-positive patients are not excluded but, to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy, if indicated\r\n* Cluster of differentiation (CD)4 count at screening >= 300 cells/mm^3\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions\r\n* If on antiretroviral therapy, must not be taking zidovudine or stavudine\r\n* Must be willing to take prophylaxis for pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm^3, whichever occurs later
+Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
+HIV.
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test
+Subjects with documentation of confirmed HIV-1 infection (i.e. HIV-positive), and a hematologic malignancy who meets all other eligibility requirements must:
+HIV-positive subjects:
+Untreatable HIV infection due to multidrug ARV resistance. Subjects with a detectable or standard viral load > 750 copies/mL should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the ARV review (described in Appendix D).
+Known HIV infection.
+Known history of HIV infection. Testing for HIV status is not necessary unless clinically indicated
+No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
+Patients who are HIV positive with an active AIDS-related illness are excluded; patients who are HIV positive but on stable therapy are not excluded.
+Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
+Seronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment
+Has AIDS (HIV positive not excluded)
+Has uncontrolled human immunodeficiency virus (HIV) (defined as HIV RNA >500 copies/ml and CD4+ count<200/mm³ on antiretroviral therapy)infection, or hepatitis B (defined as ALT > 1 x ULN, and HBV DNA >2000 IU/ml), or hepatitis C (defined as ALT > 1 x ULN, persistent viremia on antiviral therapy) infections.
+HIV or HTLV infection
+HER2 Positive
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Known active HIV, HBV or HCV infection
+For patients with unknown human immunodeficiency virus (HIV) status at the time of enrollment, HIV serology must be tested during screening; patients who are tested positive for HIV could be included if there is an adequate cluster of differentiation 4 (CD4) count (> 350/ul) on a stable regimen of highly active anti-retroviral therapy (HAART) with no detectable or minimal viral burden, and no active infections
+Patient has known human immunodeficiency virus (HIV) or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment, and disease-related symptoms may preclude accurate assessment of the safety of PBI 05204.
+All patients must be willing to undergo testing for human immunodeficiency virus (HIV) testing if not tested within the past 6 months
+If HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be eligible for study provided that their CD4+ count >= 300/uL; their viral load is undetectable; they are currently receiving highly active antiretroviral therapy (HAART)
+HIV positive patients receiving antivirals.
+Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or known human immunodeficiency virus (HIV) seropositivity; note, however, that HIV testing is not required for entry into this protocol
+Patient is human immunodeficiency virus (HIV) positive\r\nNote: patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients with a known history of HIV infection are not eligible for this trial
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Known HIV positive or AIDS
+Known human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active anti-retroviral therapy (HAART)
+Subjects with uncontrolled human immunodeficiency virus (HIV) are not eligible; controlled HIV is defined as a CD4 count > institutional lower limit of normal and no current co-infection; uncontrolled HIV is all other HIV infection; note that patients with controlled infection should be allowed to participate only if they are not receiving prohibited cytochrome P450 (CYP) interactive medications
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
+Known history of infection with human immunodeficiency virus (HIV), based on medical history (screening laboratories [labs] to rule out HIV infection are not required)
+Known carrier of HIV.
+Immune compromised patients including but not limited to: systemic immune suppressive medications within 6 weeks of enrolling; HIV-positive and below normal CD4 lymphocytes (less than 500 cells per microliter). Patients must be tested for HIV seropositivity and CD4 lymphocyte count to be eligible for the study
+Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following criteria:\r\n* CD4-positive cell count >= lower limit of institutional normal\r\n* HIV viral load < 10,000 copies HIV ribonucleic acid (RNA)/mL (if not on anti-HIV therapy) OR < 50 copies HIV RNA/mL (if on anti-HIV therapy)\r\n* No evidence of hepatitis B or C infection\r\n* No evidence of resistant strains of HIV\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining condition
+Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy are eligible for inclusion; the use of zidovudine is not allowed
+Known to be HIV positive. HIV testing is not required for those patients who are not known to be positive.
+Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must: Have a CD4 count greater than or equal to 200 cells/uL within 30 days prior to beginning study therapy; Be off all antiretroviral therapy (prophylaxis/treatment) greater than 60 days prior to beginning study therapy; Have no evidence of opportunistic infections.
+Known HIV carrier
+HIV-positive.
+Known HIV or AIDs-related illness.
+Patients with human immunodeficiency virus (HIV) infection are eligible provided they meet the following criteria: no evidence of co-infection with hepatitis B or C, cluster of differentiation (CD)4 count >= 400 cells/mm^3, no resistant viral strains, on highly active antiretroviral treatment (HAART) therapy with a viral load < 50 RNA copies/ml, and no history of acquired immunodeficiency syndrome (AIDS)-defining conditions
+Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD) 4 count less than 200 are ineligible; testing is not required in the absence of clinical findings or suspicion
+Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD)4 count less than 200 are ineligible due to potential interactions between irinotecan and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment; testing is not required in the absence of clinical findings or suspicion
+Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
+Human immunodeficiency virus (HIV)-positive patients with cluster of differentiation 4 (CD4) counts less than the lower limit of institutional normal
+History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV); subjects on immune suppressive therapy for organ transplant
+Patients known to be human immunodeficiency virus (HIV) positive; HIV testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
+HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
+Known HIV positivity on combination antiretroviral therapy; these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
+Known HIV positive.
+Known infection with HIV
+Known HIV or other history of immunodeficiency disorder.
+Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
+Known diagnosis of human immunodeficiency virus (HIV) infection unless patient is fully immunocompetent (cluster of differentiation 4 [CD4] > 200) and patient is not taking antiretroviral therapy
+Tested positive for HIV or hepatitis.
+Known HIV-positive patients and those with other acquired/inherited immunodeficiencies are ineligible due to the possibility of affecting the response to indoximod and the higher risk of active opportunistic infections.
+Participants known to be human immunodeficiency virus (HIV) positive; testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
+Known HIV positive.
+Human immunodeficiency virus (HIV)-positive patients or cancer survivors are eligible for this study if they fulfill all other eligibility criteria
+Known human immunodeficiency virus (HIV)-positive individuals; high-dose ascorbate acid is a known cytochrome P450 3A4 (CYP450 3A4) inducer, which results in lower serum levels of antiretroviral drugs; a clinical trial designed to address these interaction issues is more appropriate than this phase 1 study
+Individuals with a known history of human immunodeficiency virus (HIV) positivity may be included in the study as long as they are on appropriate highly active anti-retroviral therapy (HAART) therapy
+Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy
+HIV infection.
+Phase I: patient must not be known to be HIV-positive on combination antiretrovirals
+Expansion Cohort: patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine and must have a cluster of differentiation (CD4) count > 100/mm^3 and virus load < 5000 copies/mL; they must be placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
+Known HIV infection;
+Patients with known HIV, HBV or HCV infection (note: testing for these infections is not required).
+Sero-positive or nucleic acid test (NAT) positive for human immunodeficiency virus (HIV)
+Known chronic infectious disease including, but not limited to, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
+Patients with treated HLTV or HIV
+Hepatitis (Hep) B & C and human immunodeficiency virus (HIV)-infected patients, due to concerns in the ability to stimulate an effective immune response (determined by historical medical data)
+Patients with human immunodeficiency virus (HIV) infection are eligible provided their cluster of differentiation 4 (CD4) count is greater than or equal to the institutional lower limit of normal (LLN) (>= 334 cells/uL)
+Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
+Active infection with HIV, HBV or HCV
+Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; cluster of differentiation (CD)4+ count >= 400/mm; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV ribonucleic acid (RNA)/mL; no history of acquired immune deficiency syndrome (AIDS) defining conditions
+Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per medical doctor (MD) discretion
+History of HIV infection.
+No human immunodeficiency virus (HIV) infection; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; patients who test positive or who are known to be infected are not eligible; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
+Prior history of HIV-positivity (routine HIV testing is not required pre-treatment)
+The patient is seropositive for HIV 1, HIV 2, HBV, or HCV
+Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
+Positive test for the human immunodeficiency virus (HIV), unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) on highly active antiretroviral therapy (HAART) therapy
+Known positivity for HIV.
+Known HIV positive status
+HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time prior to study entry. HIV antigen, plasma HIV-1 RNA, or a secondary antibody test by a method other than rapid HIV and E/CIA is acceptable as an alternative test. Alternatively, if a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test is not available, two HIV-1 RNA values ? 2000 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.
+Untreatable HIV infection due to multidrug antiretroviral resistance. Patients with a detectable viral load > 750 copies/ml should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the Antiretroviral Review (described in Appendix D). This Review Committee will make the final determination as to whether HIV viremia could potentially be suppressed with alternate antiretroviral therapy. .
+Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD)4 > 300 and on stable highly active antiretroviral therapy (HAART) regimen for 1 month
+Human immunodeficiency virus (HIV) positive patients are not eligible for this protocol; hepatitis B and C positive patients will be evaluated on a case-by-case basis
+Positive serology for HIV
+HIV infection
+Subject has tested positive for HIV.
+E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
+Patients with human immunodeficiency virus (HIV) disease will be permitted, only if they are on effective anti-retroviral therapy, have a cluster of differentiation (CD) 4 count greater than 400, and have had no opportunistic infections within the past 6 months
+Known human immunodeficiency virus (HIV) positive patients; patients do not need to undergo specific screening for HIV to participate in this protocol, but those patients with known or documented infection of HIV are excluded
+For patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), the following must be true:\r\n* The patient is compliant on combination anti-retroviral therapy (CART)\r\n* The patient has cluster of differentiation (CD)4 count >= 200 at time of diagnosis
+Patients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
+Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) using combination retroviral agents which are not CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
+Patients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test\r\n* HIV testing is not required
+Known HIV-positive
+Known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.
+HIV positive or an AIDS-related illness;
+Known HIV positive
+Serious uncontrolled infection; known human immunodeficiency virus (HIV)-seropositivity requiring retroviral therapy, or diagnosis of acquired immune deficiency syndrome (AIDS); diagnosis of chronic hepatitis B or C allowed
+Patients who are HIV+ will be excluded
+Patients with known HIV.
+HIV infection
+No medical disorder that increases risks of radiation or temozolomide (TMZ) chemotherapy; no uncontrolled infection; no known positivity for human immunodeficiency virus (HIV); no other disorder limiting expected survival to < 5 years
+Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy (HAART)
+Known history of HIV or underlying immunodeficiency
+Human immunodeficiency virus (HIV) infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
+HIV infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
+HIV or HTLV I/II seropositivity
+Severe, active co-morbidity defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* Other major medical illness which requires hospitalization or precludes study therapy at the time of registration
+History of positive human immunodeficiency virus (HIV)-1 or HIV-2 serologies or nucleic acid test
+DONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid test
+Known HIV infection
+Known HIV positive.
+Evidence of HIV infection or HIV positive serology.
+Known HIV or known active HBV or HCV infection
+Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation 4 (CD4) count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral therapy (HAART) is allowed
+Evidence of HIV infection
+Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
+Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests
+HIV negative.
+Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests
+Known HIV-positive patients are excluded from the study
+Known positive status for HIV
+Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
+TREATMENT: Seronegative for HIV antibody
+If HIV-positive, any cluster of differentiation (CD)4 count will be allowed on study
+Documentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA] test kit, and confirmed by Western blot or other approved test, or HIV rapid multispot antibody differentiation assay); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n* If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subject’s HIV status
+Has a known history of HIV.
+Human Immunodeficiency Virus (HIV) negative* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
+HIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
+Patients seropositive for the human immunodeficiency virus (HIV), and/or those who are taking anti-retroviral treatment for HIV/acquired immune deficiency syndrome (AIDS)
+Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectable
+Patients with HIV
+Because of the concerns of potentially harmful interactions of TPI 287and other medications taken by patients who are HIV positive or have AIDS related diseases, patients who are HIV positive are not be eligible for entry into this study. Only patients with suspected HIV will be tested and if positive, will be ineligible.
+Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort\r\n* HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4
+Known HIV infection
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Known HIV infection.
+Patient has a known history of HIV infection (testing not mandatory).
+Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200
+Known HIV infection
+Positive for HIV infection
+Positive HIV test at screening
+Known HIV infection.
+Known human immunodeficiency virus (HIV) positive or history of acquired immune deficiency syndrome (AIDS) or AIDS-defining illness
+Known HIV positive and positive screening pregnancy test or is breast-feeding.
+HIV-positive patients are ineligible
+A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screening
+Be self-reported to be immune-compromised (human immunodeficiency virus [HIV], chronic immunomodulators, chronic corticosteroids)
+Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
+Subjects with known HIV infection
+Patients known to be HIV positive
+Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
+Positive serological test for HIV, Hep B or Hep C or history of HIV infection, Hepatitis B or Hepatitis C (women with cured HCV will be allowed; subject must have had an serologic test performed within 12 months of informed consent);
+Acquired immuno deficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment
+Patients with any evidence of severe or uncontrolled systemic disease(s) including known cases of hepatitis B or C or human immunodeficiency virus (HIV); screening for chronic conditions is not required, although patients known to have such conditions at screening should not be included
+HIV infection; patients should provide consent for HIV testing according to the institution’s standard practice
+Known HIV infection
+Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD)4 > 300 and are on a stable highly active antiretroviral therapy (HAART) regimen for 1 month prior to study enrollment
+Known history of HIV infection.
+History of positive human immunodeficiency virus (HIV)-1 or HIV-2 serologies or nucleic acid test
+DONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid test
+Known HIV infection.
+History of HIV infection.
+Is the subject HIV positive?
+Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
+Known HIV infection
+Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.
+Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with low cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or previous sirolimus use allowed
+Kown history of HIV.
+Known infection with human immunodeficiency virus (HIV) or subject has tested positive for HIV; patients without prior HIV testing will not be required to be tested
+Patients who are known to be human immunodeficiency virus (HIV) positive (+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD) 4 cells >= 500/mm^3\r\n* Viral load < 50 copies of HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies of HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART; patients who are HIV+ and do not meet all of these criteria are not eligible for this study
+Known HIV positivity or AIDS-related illness
+HIV-positive patients
+Known HIV or AIDs.
+Known HIV positivity (testing not required).
+Immunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving combination antiretroviral therapy; patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
+HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 ribonucleic acid (RNA) viral load; NOTE: The term “licensed” refers to a U.S Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV-1 RNA viral load
+HIV infection
+Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known Human Immunodeficiency Virus (HIV) disease. All HIV-positive subjects are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy.
+The patient is known to be positive for Human Immunodeficiency Virus (HIV) or has another confirmed or suspected immunosuppressive or immunodeficient condition (patients with thyroiditis are eligible)
+Known to be HIV positive or to have an AIDS-related illness.
+Positive for human immunodefinciency (HIV) infection
+Because of compromised cellular immunity and limited capacity to respond to vaccination, patients who are human immunodeficiency virus (HIV)+ will be excluded
+Concomitant diseases/conditions: a) History of a clinically relevant cardiac condition c) Known chronic liver disease. d) Active uncontrolled infection. e) Known human immunodeficiency virus (HIV) infection. f) Limitation of the patient's ability to comply with the treatment or follow-up protocol.
+No uncontrolled infection\r\n* Note: Infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
+If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4) count must be >= 400
+Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive with a CD4 count of < 400
+Positive test for HIV antibodies
+Chronic or currently active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment including, but not limited to: chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All Human Immunodeficient virus (HIV)-positive subjects are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy.
+Known positive test for HIV
+Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western Blot, or any other federally approved licensed HIV test; a positive HIV viral load prior to study entry will also be permitted
+Known human immunodeficiency virus (HIV)-seropositive and are taking anti-retrovirals may not participate in this study; participants who are HIV-seropositive and not on anti-retroviral therapy and who otherwise meet the inclusion/exclusion criteria will be eligible for the study
+Has known HIV or AIDS infection
+Known HIV or AIDS
+Known HIV or AIDS
+Known HIV or AIDS
+Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All HIV-positive patients are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy. Prophylactic antiviral and/or antibacterial antibiotics to prevent recurrence of previous infections are permitted.
+HIV positive
+Patients with acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition or patients known to be human immunodeficiency virus (HIV) positive; note, however, that HIV testing is not required for entry into this protocol; the need to exclude these patients from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
+The patient is known to be HIV-positive.
+HIV infection with a last known or suspected CD4 count of <50/mm3
+History of HIV disease and/or treatment with anti-HIV agents.
+HIV positive
+Known HIV infection
+The patient is known to be HIV-positive.
+Known HIV+ patients.
+Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Seronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Serologic evidence of HIV
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy (HIV testing not required); NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state (cluster of differentiation [CD]4 > 200, viral load undetectable, on antiretroviral therapy), are eligible for this trial
+Standard blood tests that are positive for HIV infection
+A positive HIV test result (enzyme-linked immunosorbent assay [ELISA] and Western blot) or history of known HIV; an HIV test will not be required; however, previous medical history will be reviewed
+Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection\r\n* Must be on antiretroviral therapy and there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment\r\n* HIV viral load must be < 200 copies/ mm^3 by standard clinical assays
+Subject has active infection with HIV, HBV, HCV or HTLV as defined below:
+Positive serology for HIV
+Known HIV positive.
+Known HIV positive patients.
+Subject is HIV positive
+No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case?by?case basis
+HIV-1 infection, as documented by a rapid HIV-1 test or any Food and Drug Administration (FDA)-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry; alternatively, two HIV-1 RNA values > 200 copies/mL at least 24 hours apart performed by any laboratory that has Clinical Laboratory Improvement Amendments (CLIA) certification, or its equivalent may be used to document infection
+Self-reported or documented history of pre-existing peripheral neuropathy due to diabetes, human immunodeficiency virus (HIV), or other conditions
+Severe, active co-morbidity defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months\r\n* Transmural myocardial infarction within the last 6 months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of registration\r\n* Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Renal tubular acidosis or metabolic acidosis\r\n* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol
+Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)
+Known history of human immunodeficiency virus (HIV). Subjects should be tested for HIV prior to Randomization if required by local regulations or EC;
+Positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
+HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n** NOTE: A “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
+Subjects known to be seropositive for HIV or for HTLV-I
+Males who self-identify as having had or currently having sex with men; both human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects are being enrolled
+Immunocompromised (positive human immunodeficiency virus [HIV] test, transplant recipient, received chemotherapy for cancer, or taking immunosuppressant drugs)
+HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
+Patients seropositive for HIV-1 or -2
+Participants with a known diagnosis of human immunodeficiency virus (HIV); Note: an HIV screening test does not have to be performed to evaluate this criterion
+Immune deficiency disease or known history of HIV, HBV, HCV
+Known active infection with HIV
+Known HIV infection.
+Known active infection with HIV
+HIV-1 infection, documented by one of the following any time prior to study entry:\r\n* Any licensed rapid HIV test\r\n* HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit; and confirmed by one of the following:\r\n* Licensed western blot\r\n* Second antibody test by a method other than the initial rapid HIV and/or E/CIA\r\n* HIV-1 antigen\r\n* Plasma HIV-1 RNA viral load\r\n* Documentation of receipt of antiretroviral therapy\r\n* Note: the term “licensed” refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV-1 RNA viral load
+No human immunodeficiency virus (HIV) disease (patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies)
+Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment
+Positive HIV test
+Positive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if tested), HTLV-2 (if tested), or WNV (if tested)
+Acquired immunosuppressive diseases such as active human immunodeficiency virus (HIV) infection or congenital diseases of immunity
+Patients who have HIV, Hepatitis A, B or C or CMV reactivation
+Evidence of HIV infection or known HIV positive serology.
+Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator
+Donors who are HIV positive (Patients who are HIV positive - if autologous product)
+HIV-positive patient at Thomas Street Health Center
+Known history of HIV seropositivity;
+HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay [ELISA], Western blot or other approved test); alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests; if the participant’s HIV status is documented by an outside physician, the protocol team strongly recommends obtaining a copy of the HIV laboratory reports from this physician; all confirmatory tests and the physician’s note must be on file before the participant is enrolled; in the rare circumstance where only an outside physician’s note with no supporting laboratory documentation is available, the local site should have additional tests performed to verify the participant’s HIV status; one of the following additional tests should be performed:\r\n* A rapid HIV test\r\n* ELISA and Western blot\r\n* Chemiluminescence immunoassay and Western blot\r\n* HIV ribonucleic acid (RNA) > 2000 copies/mL\r\n* HIV antigen test
+Immune compromised individuals (human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS], immuno-suppressive drug therapy)
+Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive (HIV 1/2 antibodies) and currently receiving antiretroviral therapy
+Patients who are known to be human immunodeficiency virus (HIV)-positive will be excluded as highly active antiretroviral therapy (HAART) and HIV itself are known to cause peripheral neuropathy
+Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis
+HIV positive
+Any HIV status
+Known HIV or AIDS-related illness
+The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
+Human immunodeficiency virus (HIV)+ positive patients are eligible if their CD4+ count >= 300/uL and they have an undetectable viral load; in addition, they must be currently receiving highly active antiretroviral therapy (HAART) and be under the care of an infectious diseases specialist
+Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:\r\n* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months\r\n* They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts\r\n* They have an undetectable viral load on standard assays
+Positive serology for HIV.